CD47 and neoplasm: For instance, IBI322, was designed to improve therapeutic selectivity and efficacy by preferentially binding to PD-L1+CD47+ tumor cells, inducing tumor cell phagocytosis while minimizing impact on CD47+PD-L1− cells like red blood cells [91].